Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EBT (2016 - 2025)

Zevra Therapeutics' EBT history spans 11 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, EBT rose 162.19% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $86.7 million, up 196.16%, while the annual FY2025 figure was $86.7 million, 196.16% up from the prior year.
  • EBT reached $12.7 million in Q4 2025 per ZVRA's latest filing, up from -$977000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $76.9 million in Q2 2025 to a low of -$33.2 million in Q3 2024.
  • Average EBT over 5 years is -$4.6 million, with a median of -$4.8 million recorded in 2022.
  • Peak YoY movement for EBT: surged 622.12% in 2021, then tumbled 650.09% in 2024.
  • A 5-year view of EBT shows it stood at -$2.7 million in 2021, then fell by 12.63% to -$3.0 million in 2022, then tumbled by 561.74% to -$19.9 million in 2023, then decreased by 2.39% to -$20.4 million in 2024, then surged by 162.19% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's EBT are $12.7 million (Q4 2025), -$977000.0 (Q3 2025), and $76.9 million (Q2 2025).